HC Wainwright & Co. Initiates Coverage On PaxMedica with Buy Rating, Announces Price Target of $3
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has initiated coverage on PaxMedica (NASDAQ:PXMD) with a Buy rating and set a price target of $3. This new coverage could influence investor sentiment and potentially impact PXMD's stock price in the short term.
December 04, 2023 | 11:45 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
PaxMedica, now covered by HC Wainwright & Co. with a Buy rating and a $3 price target, may see increased investor interest and a positive impact on its stock price in the short term.
Analyst coverage, especially with a Buy rating, often leads to increased visibility and credibility among investors, which can result in a positive short-term price movement. The announcement of a price target also provides a benchmark that can influence investor expectations and trading behavior.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100